Downregulation of Raf-1 kinase inhibitory protein as a sorafenib resistance mechanism in hepatocellular carcinoma cell lines.

Jin Sun KimGwang Hyeon ChoiYusun JungKang Mo KimSe-Jin JangEun Sil YuHan Chu Lee

Published in: Journal of cancer research and clinical oncology (2018)

Reactivation of the Raf/MEK/ERK pathway through aberrant expression of RKIP is one of the mechanisms behind sorafenib resistance in HCC. Sequential combination treatment with sorafenib and PD98059 could provide a new strategy to overcome sorafenib resistance in future clinical studies.

Keyphrases

signaling pathway
cell proliferation
poor prognosis
binding protein
tyrosine kinase
long non coding rna
amino acid
protein kinase